Altesa BioSciences Reports Positive Phase 2 Vapendavir Data in COPD
ORLANDO, Fla., May 19, 2026 Altesa BioSciences announced positive results from its randomized, placebo-controlled Phase 2 rhinovirus challenge study...
antiviral therapy
Advertisement
Cocrystal Pharma Advances CDI-988 for Norovirus Care
BOTHELL, Wash., April 30, 2026 Cocrystal Pharma, Inc., a clinical-stage biotechnology company focused on antiviral therapeutics, has presented new...
Aligos-Amoytop $445M HBV Licensing Deal Expands Access
SOUTH SAN FRANCISCO, Calif., April 16, 2026 Aligos Therapeutics has entered into an exclusive licensing agreement with Xiamen Amoytop...
Aligos Therapeutics Gains Fast Track for HBV Drug
SOUTH SAN FRANCISCO, Calif., April 14, 2026 Aligos Therapeutics, Inc. has announced encouraging progress in its Phase 2 B-SUPREME...
GSK Bepirovirsen Wins EMA Review for Hepatitis B Drug
London, UK | March 27, 2026 EMA Accepts First-in-Class Hepatitis B Therapy for Review GSK has announced that the...
Advertisements
Vir Completes Phase 3 Enrollment for Hepatitis Delta Trial
San Francisco, California – November 3, 2025 Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on harnessing...
Advertisement
